Metraipolis › archive › dc_5779bbec6652

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter… — Europe PMC PMID:41335575

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41335575
DOI: 10.1097/hc9.0000000000000859
License (as archived): solo-consultazione
Archived: 2026-11-07T23:27:45.946Z
SHA-256 of the archived text: bf71afcc10d51bcfd3e6c3645648010579b0b56b02bcc776f3c3e3c7f4b709fb
Stable URL of this page: https://metraipolis.com/documento/dc_5779bbec6652

How to cite

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter… — Europe PMC PMID:41335575 — Europe PMC (en), https://europepmc.org/article/MED/41335575 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5779bbec6652 (Metraipolis archive dc_5779bbec6652, sha256 bf71afcc10d51bcfd3e6c3645648010579b0b56b02bcc776f3c3e3c7f4b709fb)

BibTeX

@misc{dc5779bbec6652,
  title = {Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter… — Europe PMC PMID:41335575},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41335575},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5779bbec6652; sha256 bf71afcc10d51bcfd3e6c3645648010579b0b56b02bcc776f3c3e3c7f4b709fb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41335575. Agents can read the archived copy with the MCP tool read_document.